Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cryoablation and Anti-PD-L1 Immunotherapy for Triple Negative Breast Cancer (TNBC)

NCT04249167 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04249167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04249167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cryoablation and Anti-PD-L1 Immunotherapy for Triple Negative Breast Cancer (TNBC)
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Withdrawn
Start date
January 23, 2020
Completion date
November 17, 2021
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iii breast cancer ajcc v8, anatomic stage iiia breast cancer ajcc v8, anatomic stage iiib breast cancer ajcc v8, anatomic stage iiic breast cancer ajcc v8, anatomic stage iv breast cancer ajcc v8, locally advanced breast carcinoma, metastatic triple-negative breast carcinoma, prognostic stage iii breast cancer ajcc v8, prognostic stage iiia breast cancer ajcc v8, prognostic stage iiib breast cancer ajcc v8, prognostic stage iiic breast cancer ajcc v8, prognostic stage iv breast cancer ajcc v8